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Abstract— Objective: An imaging device to locate functionalised 
nanoparticles, whereby therapeutic agents are transported from 
the site of administration specifically to diseased tissues, remains 
a challenge for pharmaceutical research. Here, we show a new 
method based on electrical impedance tomography (EIT) to 
provide images of the location of gold nanoparticles (GNPs) and 
the excitation of GNPs with radio frequencies (RF) to change 
impedance permitting an estimation of their location in cell models 
Methods: We have created an imaging system using quantum 
cluster GNPs as contrast agent, activated with RF fields to heat the 
functionalized GNPs, which causes a change in impedance in the 
surrounding region. This change is then identified with EIT. 
Results: Images of impedance changes of around 80±4% are 
obtained for a sample of citrate stabilized GNPs in a solution of 
phosphate-buffered saline. A second quantification was carried 
out using colorectal cancer cells incubated with culture media, and 
the internalization of GNPs into the colorectal cancer cells was 
undertaken to compare them with the EIT images. When the cells 
were incubated with functionalised GNPs, the change was more 
apparent, approximately 40±2%. This change was reflected in the 
EIT image as the cell area was more clearly identifiable from the 
rest of the area. Significance: EIT can be used as a new method to 
locate functionalized GNPs in human cells and help in the 
development of GNP-based drugs in humans to improve their 
efficacy in the future. 
 
Index Terms—Electrical impedance tomography (EIT), 
colorectal cells, gold nanoparticles, radio frequencies, impedance 
change. 
I. INTRODUCTION 
ARGETED drug delivery, whereby therapeutic agents are 
transported from the site of administration specifically to 
diseased tissues, remains a key issue of pharmaceutical 
research. Nanomedicine, which employs nanoparticle-mediated 
drug delivery can be used to overcome this problem in 
conventional drug delivery [1]. Ultra-small nanoparticles that 
can permeate vessels and move by convection in tissues and 
cross tissue barriers can be loaded with drugs and can be 
retained in in specific diseased tissue locations in the body 
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limiting interaction with healthy tissue. The goal is to localise 
and prolong, drug delivery to focus drug interaction with the 
diseased tissue. The advantages of this approach are the 
reduction in the frequency of the dosages taken by the patient 
and the obtainment of a uniform effect of the drug, that results 
in minimisation of drug side effects [1]. Transported drugs from 
the site of administration specifically to diseased tissues, has yet 
to be achieved. However, targeted delivery would address some 
of the present limitations and has significant potential to reduce 
side effects from chemotherapeutic drugs. The development of 
advanced drug delivery systems (DDS) using pharmaceutical 
nanotechnology with the capacity to transport small-molecule 
drugs to tumours, would provide reduced systemic toxicity and 
improved treatment outcomes [2]. New tools are required to 
facilitate customisation of therapy based on the specific needs 
of individual patients. In the drug delivery paradigm, imaging 
may be used to identify the target and non-target anatomy or for 
screening, planning, monitoring, and postprocedural 
assessment of treatment outcome [3]. 
At present the following methods can be used to track drugs: 
mass spectrometry (MS) [4] [5], magnetic resonance imaging 
(MRI) [6], positron emission tomography (PET) [7] and 
computer tomography (CT). However, there are many 
limitations with the usage nanotechnology with these 
technologies [8]. MS is not a practical technology for use in 
humans and requires considerable computer processing to build 
three-dimensional images of the drug location. [9]. Tracking 
drugs using MS is undertaken with animal experiments 
requiring large scale computing to provide only one image of 
the accumulation of the drug [10]. PET uses ionizing radiation 
and requires many minutes to create its images. This technology 
cannot be used during surgical intervention. It also needs a 
contrast agent injected into the body and the range of these that 
are available for PET are not comprehensive or ideal for 
creating new drugs. CT can track gold nanoparticles (GNPs) but 
also uses ionizing radiation which limit its use for locating the 
GNPs. Another limitation is the size; GNPs with gold core less 
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than 2 nm do not have any measurable plasmonic, which is 
required to image them. MRI can also use a contrast agent in 
the form of gadoterate meglumine (Gd-DOTA) but this is not 
ideal as a scaffold to create new drugs. GNPs are more suited 
as a scaffold to create new drugs, but unfortunately, MRI cannot 
use them, as they are not magnetic and cannot be seen in the 
MRI 12]. PET, CT and MRI produce static images unlike the 
new method proposed in this paper that can produce dynamic 
images in real-time. 
 
A. GNPs as Contrast Agents 
GNPs are more suited as a scaffold to create new drugs and 
can be used as contrast agents to track particular physiological 
processes during imaging [13]. Particles below 5 nm diameter 
including the attached ligands can be cleared rapidly by the 
body’s reticuloendothelial system following injection into the 
bloodstream. Methods based on plasmonic GNPs for cancer 
diagnosis and photothermal therapy are being investigated, due 
to the optical properties. The surface plasmon resonance (SPR), 
a unique phenomenon to plasmonic (noble metal) nanoparticles 
produces a strong electromagnetic field on the particle surface 
and enhances all the radiative properties such as absorption and 
scattering. The heating efficiencies and spectral ranges vary 
with the type of nanoparticle. However, for GNPs with attached 
ligands that have a core of size below 2 nm, there is no 
phenomenon to plasmonic resonates [14] which is in the size 
range currently being developed for immunotherapy. GNPs are 
more suited as a scaffold to create new drugs, but unfortunately, 
MRI cannot use them, as they are not magnetic and cannot be 
seen in MRI. 
Previous research suggested that GNPs has the potential as a 
contrast agent for bioimpedance measurements [15] and it is 
possible to detect cancer cells based on the impedance increase 
[16]. However, the addition of GNPs to decrease impedance in 
cancer cells would limit the ability to distinguish between GNPs 
and cancer cells. 
B. Bioimpedance Imaging 
To address this, we have created an imaging system using 
quantum cluster GNPs [17] as contrast agent, activated with 
radio frequency (RF) fields to heat the functionalized GNPs, 
causing a change in impedance around them. This change is 
then identified with electrical impedance tomography (EIT). 
EIT is a non-invasive, radiation free technique that images an 
object by injecting small sinusoidal currents through electrodes 
on its boundary, and measures the resulting potentials 
developed on the same or other electrodes. This process permits 
the estimation of the distribution of the inner conductance 
(impedance) of the object with high temporal resolution (~120 
images per second [18]. Clinical studies have already been 
undertaken demonstrating in potential for use on humans [19]. 
A clinical study of 200 neonates for 72 hours each was 
undertaken during the CRADL project [cradlproject.org]. 
EIT is sensitive to temperature changes causing the 
impedance to change [20]. This allows the creation of images 
of temperature changes. Also, multifrequency EIT which is 
based on the principle of electrochemical impedance 
spectroscopy [16] can provide images of cancer regions based 
on the structure of the cells. It would allow this new method to 
provide an image of the tumor cells and the location of the 
immune system drug [21], [22]. 
This paper presents of a novel EIT method to locate 
nanoparticles below 5 nm diameter in human tissue. This new 
approach has a number of advantages in comparison with other 
methods that are currently used to locate GNPs in human tissue. 
The rest of this paper is organized as follows. Section II 
provides the methods for the imaging system and the cell 
models. In Sections III and IV, the obtained results are 
presented and discussed, respectively. Section V provides 
concluding remarks with promising directions for future 
research. 
II. METHOD AND MATERIALS 
A. Optimal Frequency for GNP Heating 
Experiments have already demonstrated that GNPs can be 
heated with RF [23], [24], [25]. The size and the biological 
material (ligands) attached to the nanoparticle changes the 
frequencies at which heating is obtained [26]. To address this 
and to identify an optimal frequency for GNP heating for 
further experimentation, we considered the frequencies where 
the lowest heating rate of the solution based only on the medium 
(PBS) occurred. Furthermore, we considered the frequencies 
where the heating rate of the solution that contained GNPs was 
sufficiently higher than the rate of the PBS-based solution. 
From a practical point of view, these criteria prevent the risk of 
human tissue damage during the therapy. 
In this experiment, for frequencies between 2.265 GHz and 
2.7 GHz, eppendorfs containing 1.5 ml of PBS and Citrate 
stabilized GNPs (GNP-CS) solutions, respectively, were placed 
one by one in the waveguide, on the Kapton film, see Fig. 1. 
The waveguide setup was driven by a Marconi Instruments 
2031 RF signal generator at 0 dBm for 30 minutes, and the 
temperature of the solutions was measured with fast immersion 
probes [27] connected to a Luxtron 812 fiber optic 
thermometer. 
B. RF System and Waveguide 
The PCB-unit was mounted on a WG10 waveguide that was 
 
Fig. 1.  Schematic of the experimental set-up. The set-up consisted of the EIT 
system (2) which was connected to the 32-electrode PCB (7) placed inside the 
waveguide (3), on the Kapton window (6). The waveguide (3) was driven by 
the RF signal generator (4) and powered by the amplifier (5). All the images 












custom designed with a cut-off frequency range of 2.07 GHz to 
4.15 GHz (Global Invacom Waveguide, UK). The waveguide 
consisted of four main parts: a 320 mm fixed load, two 200 mm 
precision straights and a coaxial adaptor; all made of silver-
finished brass. A pressure flange fitted with a Kapton window 
was used to stabilize the system and was fitted with a 
transparent 3D-printed holder to keep the samples in place. The 
waveguide was driven by a signal generator (Marconi 
Instruments 2031 RF signal generator, operating from 10 kHz 
to 2.7 GHz) at 0 dBm which was amplified by a 5-Watt power 
amplifier. The power amplifier could provide a maximum 
power of 5 W in the frequency range of 800 MHz to 4.2 GHz 
(Amplifier Research model 5S1G4, USA). 
C. EIT System 
The system used for EIT imaging is the Pioneer set from 
SenTec AG [28]. It consists of an advanced interface with 32 
channels, a smart sensor belt connector, a power supply unit and 
data communication documentation. The system is capable of 
injecting programmable currents from 1 mA to 7 mA peak in 
the frequency range of 50 kHz to 250 kHz. It can provide 
different data frame rates per second (fps). The SenTec EIT 
monitor software (STEM) allows setting of EIT parameters 
such as excitation frequency and injection current. It provides 
real-time monitoring of the signals and continuous quality 
checks of each one of the electrodes. The raw data can be stored 
for post-processing and signal analysis. Unless stated 
otherwise, all experiments were recorded at 1 fps; the injected 
current was 7 mA at 250 kHz. The raw data extracted was 
analyzed in MATLAB and EIDORS software [29] to 
reconstruct the images. The reconstruction algorithm was based 
on difference imaging with respect to the reference image by 
using GREIT algorithm [30]. All measurements were recorded 
for 7 minutes; during the first 2 minutes the power amplifier 
was off. The images from this period were used as the reference. 
Then the power amplifier was turned on for 5 minutes while 
continuous live monitoring of the samples was recorded. 
A cell model was created consisting of colon epithelial and 
colorectal cancer cells with GNPs in cancer cells. This cell 
model was placed in a custom-made ring of 32 gold-plated 
electrodes of size 1 mm × 1.5 mm utilized to be interfaced with 
the EIT system (see the structural representation of the EIT-
based system in Fig. 2). A well of 2.9 cm diameter, 1 cm height 
and 1 mm thickness was designed and placed onto the PCB-unit 
to contain the samples within the electrode ring during the 
experiments. Each electrode was connected to the EIT system 
by a ribbon cable. 
D. Preparation and Analysis of GNP 
GNP-CS were used with a core size of 5 nm diameter and 
mass concentration of 0.06 mg/mL (NP01-0051010, 
ClineScientific, UK [31]) and an optical density of 1. The 
hydrodynamic diameter and SPR peak for these GNP-CS were 
verified and confirmed via dynamic light scattering (DLS) and 
ultraviolet-visible spectroscopy (UV-vis), respectively. The 
GNP-CS were purified with centrifugal filter units (Amicon® 
Ultra-15, cut-off 10kDa), and re-suspended in phosphate-
buffered saline (PBS) (DPBS 1X Gibco™, ThermoFisher, UK) 
7.17 pH before use. 
GNPs stabilized with glutathione (GSH) were synthesized by 
adapting a similar method [32]. Briefly, 0.01 mM of 
tetrachloroauric acid (HAuCl4.3H2O) was dissolved in 10 mL 
of DiH2O, to which a freshly prepared sodium borohydrate 
(NaBH4) solution (0.015mM) was added dropwise, stirring at 
25 ◦C until the solution color changed to deep red. Then, 50 µl 
of glutathione (GSH, 0.2 mM) was added and stirred for 1 hour. 
The free GSH molecules were removed by centrifugation with 
10 kDa centrifugal filter units. 
The stock GNP-GSH solution was used to produce folic acid 
functionalized GNPs (GNP-FA) via 1-(3- 
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride-N-
hydroxysuccinimide (EDC-NHS) linkage. 10 mL of stock 
GNP-GSH solution, 25 µl of EDC (50 mM) and 25 µl of NHS 
(50 mM) were added, stirred for 1 hour before adding folic acid 
(0.01 mM), and stirred overnight. Unbound folic acid was 
removed with centrifugal filter units (Amicon® Ultra-15, cut-
off 30 kDa) and the GNP-FA solution was kept at 5 ◦C until 
needed. Folic acid binding was confirmed via UV-vis 
(FLUOstar Omega, BMG Labtech, Germany) and DLS 
(Zetasizer Nano ZS, Malvern Panalytical, UK) studies. The 
concentration of folic acid bound to the GNPs was calculated to 
be 1.1×10-4M, through Beer-Lambert law (𝐴 = 𝜀𝑙𝐶); FA 
extinction coefficient 𝜀=15,760M-1cm-1, path-length 𝑙 = 1 cm, 
and absorbance 𝐴 = 1.736. 
For cell uptake detection, fluorescein isothiocyanate (FITC) 
was added to stock GNP-FA solution at 0.1 M concentration 
and allowed to react overnight in an orbital shaker, at room 
temperature, in the dark. Unbound FITC was removed via 
centrifuging as previously described. Deionized water used 
throughout experiments was maintained at >1 MΩ with a lab 
deionization unit (Select Analyst, SUEZ Water Technologies & 
Solutions, France). 
 
Fig. 2.  Structural representation of the EIT-based imaging system consisting 
of a ring of 32 gold-plated electrodes of size 1 mm × 1.5 mm utilized to be 
interfaced with the EIT system. A well of 2.9 cm diameter, 1 cm height and 1 





E. Influence of RF Field on Citrate GNPs 
To increase the concentration of the stock GNP-CS solution, 
1 mL aliquots (3.21·10-4M) were filtered with centrifugal filter 
units and the obtained pellets kept at 4 ◦C. PCB-units containing 
either 2 mL PBS or 1.9 mL PBS were placed one at the time on 
the waveguide as shown in Fig. 1. The PCB-unit containing 1.9 
mL PBS, the 100µl pellet of GNP-CS was pipetted in the center 
of the electrode ring before the reference was recorded. Each 
RF experiment was recorded with the EIT system as described 
previously. UV-vis spectra were recorded to confirm the GNPs 
did not aggregate following RF excitation. 
F. Cell Lines and Culturing 
Human Duke’s B Colorectal Cancer (CRL2159, ATCC no. 
LS411N) and colon epithelial (CRL1790, ATCC no. CCD841) 
cell lines were obtained from LGC Standards-ATCC. CRL2159 
and CRL1790 were cultured with RPMI-1640 (product no. 
R8758) and MEM (product no. M4655) respectively, both 
containing 10% foetal bovine serum and 1% pen-strep solution. 
Cells were maintained inside an incubator with humidified 
atmosphere containing 5% CO2 at 37 ◦C. 
G. In-Vitro Uptake Studies 
After culturing CRL2159 and CRL1790 as mentioned above, 
both were trypsinized. Approximately 10,000 cells of each cell 
line were pipetted onto separate sterilized 13 mm diameter 
cover-slips placed in separate 6-well plates, covered with 
medium and maintained in the incubator to reach 80-90% 
confluence (final cell count CRL1790 = 1.15×105 and 
CRL2159 = 1×106 per cover-slip).  
To visualize folate receptor alpha (FR-α) expression, plates 
with each cell line were washed 3 times with PBS and fixed 
with 4% paraformaldehyde (PFA) for 30 minutes. Residual 
PFA was washed twice with PBS, followed by treating the fixed 
cells with citrate buffer at pH 6 for 10 minutes. After washing, 
the cells were treated with 50% horse serum in PBS (1:1), 
followed by incubation with 1:100 concentrated FR-α rabbit 
polyclonal antibody (PA5-42004, Thermofisher) for 90 
minutes. The cells were further incubated after washing with 
biotinylated-secondary antibody (VECTASTATIN ABC kit, 
Vector laboratories Ltd, UK) for 30 minutes. Finally, the cells 
were incubated with tertiary peroxidase-labelled avidin for 20 
minutes before developing with a tyramide signal amplification 
(TSA) fluorescein system (NEN Life Science, USA). After 
washing again with PBS, the cover-slips were mounted onto 
slides using DAPI (4′,6-diamidino-2-phenylindole) based 
mounting media (VECTASHIELD®, Vector laboratories Ltd, 
UK). FR-α expression was visualized with a Leica TCS SP2 
confocal microscope. 
To visualize GNP internalization, plates with each cell line 
were incubated with 400 µl of FITC bound GNP-FA at 1×10-7 
M concentration for 3 hours. The media was discarded, and any 
non-bound GNP-FA washed away with PBS. The cells were 
fixed with PFA for 30 minutes, followed by mounting and 
visualization as described above. 
 
H. Influence of RF on GNP Incubated CRL2159 
Cover-slips containing CRL2159 cells were prepared as 
above and maintained in the incubator. Cells were incubated 
with 400ul of either RPMI, GNP-CS (3.21·10-4M) or GNP-FA 
(3.21·10-4M) for 3 hours. After which the media was discarded, 
cells washed with PBS and covered with fresh RPMI until use. 
Each cover-slip was placed in a PCB-unit, covered with 1 mL 
RPMI and placed inside the waveguide. After a brief period of 
acclimatization, each PCB-unit was placed inside the 
waveguide and the RF exposure recorded as described 
previously. 
III. RESULTS 
A. Optimal Frequency for GNP Heating 
As an optimal frequency for heating GNPs, we consider a 
frequency, at which the following phenomena are observed: (1) 
the heating rate of the background is low, i.e., we expect that 
human tissue will not be damaged at the optimal frequency; (2) 
GNPs are expected to be heated when condition (1) takes place, 
and the heating rate of nanoparticles is higher than the heating 
rate of the surrounding medium. Fig. 3 shows results on heating 
rate of PBS and GNP-CS solutions that have been excited for 
30 minutes at different frequencies in the microwave regime. 
Note that the results are demonstrated only for frequencies at 
which the heating rate of GNPs is higher than the heating rate 
of PBS, and for the initial frequencies (lower and higher) where 
this observation shifted toward higher heating rate of PBS. Over 
the remaining part of the frequency band (2.265 GHz, 2.7 GHz), 
PBS rate of temperature change was consistently higher than 
that of the GNP solution. Furthermore, there was no linear 
correlation observed between the rates of temperature increase. 
B. Analysis of Synthesized GNPs 
UV-vis and DLS analyses were performed to confirm the 
synthesis of GNPs-GSH, as well as to confirm the subsequent 
attachment of folic acid (FA) to the GNPs. Fig. 4 shows the 
absorption spectra for GNPs-GSH with no SPR peak at 520 nm 
as expected from particles <2 nm, where a peak was seen after 
 
Fig. 3.  The heating rate difference between PBS and GNP-CS solutions during 
30 minutes exposure at different frequencies. The figure contains only the key 
frequencies at which the heating rate of GNPs is either close or higher than the 





FA addition, confirming the synthesis of GNPs-FA. The size 
obtained from DLS quantified the size of GNPs-GSH to 1.9±0.3 
nm and GNPs-FA to 3.4±1.4 nm and confirmed a narrow size 
distribution of the synthesized particles; see Fig. 5. 
C. Locations of GNPs in Solution With EIT 
Fig. 6 shows the EIT image reconstructions obtained after 
exposing PBS (Fig. 6(a)) and PBS with added GNP-CS (Fig. 
6(b)) to a RF field. Both solutions were recorded for 1 minute 
without an active RF field to establish the reference, followed 
by exposure to RF at 2.5999GHz for 5 minutes. To avoid 
complete homogenisation of the GNPs with PBS, the aliquot 
was added just before taking the reference, as shown in Fig. 
6(c)). 
Difference imaging of the PBS solution showed a slight 
change of color, with a calculated change of 25%. Adding the 
GNP-CS aliquot to a fresh PBS solution gave around 80% of 
change in the EIT image. Twenty repeats for both samples were 
made, using fresh solutions for each measurement, provided a 
standard deviation of <0.4% for PBS and with added GNP-CS 
a standard deviation about 4.37%; see Table I. 
D. In-Vitro Uptake Studies 
Confirming the internalization of GNPs into the colorectal 
cancer cells was undertaken in order to compare them with the 
EIT images. GNP-FA were further functionalized with FITC, a 
fluorescent moiety, which allowed simple visualization with 
confocal microscopy [33]. FITC used in the experiments has a 
reactive isothiocyanate group that can react and bind with 
amine and sulfhydryl groups. It had reacted with amine group 
in glutathione and bonded with it and in turn signals folic acid 
bound to GNPs in the cells in vitro. Colorectal cancer cells 
(CRL2159) were chosen due to over-expression of folate 
receptor around their surface and were cultured using standard 
practices, along with colon epithelial cells (CRL1790), in order 
to assess the differences in internalization with cells which do 
not present folate receptor [34], [35]. The in vitro uptake studies 
were carried out separately on both cell lines since use of 
different media prohibits co-culturing; besides cancer cells 
compete for the nutrition in the media starving normal cells 
[36]. In order to confirm folate receptor alpha expression, anti-
FR-α antibodies were used to target the receptors, while the 
biotin-avidin interaction of secondary and tertiary antibodies 
enabled their visualization. Fig. 7 shows images resulting from 
immunocytochemistry staining and confocal imaging of 
CRL1790 and CRL2159 cells. CRL1790 cells (Fig. 7(a)) shows 
no evidence of the green fluorescent signal expected for the 
receptors, while showing clear defined nuclei in blue, from 
DAPI counter-staining. A strong green fluorescent signal was 
present for CRL2159 cells (Fig. 7(b)), which shows strong 
over-expression of FR-α receptors. 
Both cell lines were incubated with GNP-FA (1·10-7 M) for 
 
Fig. 4.  UV-vis absorbance spectra obtained from synthesis of GNP-GSH and 
after functionalization with folic acid – GNP-FA. 
 
















Fig. 5.  Size distribution obtained via analysis of GNP-GSH synthesis and after 
FA functionalization. 
  


















Fig. 6. EIT reconstructed images obtained after exposing PBS (a) and PBS 
with added GNP-CS (b) to a RF field. The position of GNP-CS on the PCB-
unit is depicted in (c). Both solutions were recorded for 1 minute without an 
active RF field to establish the reference, followed by exposure to RF at 2.5999 
GHz for 5 minutes. 








































c) GNPs positioned on the PCB-unit
TABLE I 
MEAN-VALUE PERCENTAGE CHANGE AND STANDARD DEVIATION OF 
RESULTS OBTAINED FROM EIT OF PBS AND PBS+GNPS 
Solution Mean Value (%) Standard Deviation (%) 
PBS 24.961 0.338 





3 hours, after which any non-bounded nanoparticles were 
washed off before fixing and staining the cells to evaluate the 
presence of GNPs in the colorectal cancer cells. The nuclei were 
counterstained with DAPI and stained blue while any present 
GNP-FA would show green, fluorescent staining. Here, 
internalization is showed indirectly by the fluorescence 
quenching mechanism. Due to the small SPR wavelength of the 
GNPs, as long as glutathione-folate ligand was conjugated with 
GNPs, fluorescent remained quenched. However, upon 
internalization in the cell the ligands on the GNPs surface 
displaces which leads to no fluorescent quenching and 
visualization of the displaced glutathione-folate ligand. Fig. 7 
shows the confocal images obtained for colon epithelial cells 
(Fig. 7(c)) and colorectal cancer cells (Fig. 7(d)). It is evident 
from the Fig. 7(c) that no GNP-FA were internalized by the 
colon epithelial cells, whereas colorectal cancer cells show 
strong fluorescent signals in the cell cytoplasm indicating the 
presence of internalized GNP-FA [37]. 
E. Visualization of GNPs in Colorectal Cancer Cells Using 
EIT 
Coverslips containing colorectal cancer cells were incubated 
with culture media, GNP-CS, or GNP-FA. Once the reference 
was taken, all sets were exposed to an RF field for 5 minutes 
(temperature change less than one degree) and the resultant EIT 
images are shown in Figs. 8(a)-(c). Images obtained with 
colorectal cancer cells and no added GNPs showed a very slight 
change of color and the difference to the reference was 
calculated to around 8%. When incubating the cells with citrate-
coated GNPs the change after RF exposure increased to 18%, 
and the area where cells were located was slightly brighter than 
the remaining area. When the cells were incubated with 
functionalized GNPs (GNP-FA), the change of color was more 
apparent and was calculated to approximately 42%. This 
change reflected on the EIT image as the cell area was more 
clearly identifiable from the rest of the area. In order to confirm 
the changes seen in the EIT images were not due to artefacts, 
the experiment was repeated twenty times, from incubation to 
visualization. Repeats without added GNPs demonstrated a 
standard deviation about 0.34%, while repeating the EIT 
recording with GNP-CS or GNP-FA provided a standard 
deviation below 3%; see Table II. 
Human normal colon epithelium cells were incubated with 
culture media only and exposed to an RF field for 5 minutes as 
negative control for EIT cell damage. The images obtained 
showed negligible changes to the reference of around 6%; see 
Fig. 8(d). 
IV. DISCUSSION 
When the nanoparticles within the cancer cells are stimulated 
with the RF-field, they produce a small change in temperature 
(less than one degree). The temperature difference corresponds 
to an impedance change due to the disruption of ions flowing in 
the cells. Since the reconstructed EIT images produce a 
difference image based on the pre and post RF stimulation of 
the nanoparticles, this enables us to estimate the location of the 
GNPs. Furthermore, the approach can be repeated to identify 
whether the location of particles has been changed. 
 
Fig. 7. Shows the expression of FR-α receptors in colorectal cancer cells [(a) 
and (b)] and GNP-FA internalisation [(c) and (d)] using a confocal microscope. 
Scale bar = 50 µm. Magnification 40X. (a) human colon epithelium cells 
showing negative expression for FR--α receptors (b) colorectal cancer cells 
showing positive expression for FR--α receptors (in green) (c) human colon 
epithelium cells showing no GNP-FA internalisation (d) colorectal cancer cells 












MEAN-VALUE PERCENTAGE CHANGE AND STANDARD DEVIATION OF 
RESULTS OBTAINED FROM EIT OF CANCER CELLS, WITH OR WITHOUT GNP 
INCUBATION 
Solution Mean Value (%) Standard Deviation 
(%) 
CRL2159 7.944 0.395 
CRL2159 + GNPs-CS 17.220 1.303 
CRL2159 + GNPs-FA 39.753 2.014 
 
 
Fig. 8.  Human colorectal cancer cells grown in cell culture media, were 
incubated with (a) no GNPs, (b) GNP-CS solution, (c) GNP-FA solution. After 
RF exposure for 5 minutes, EIT reconstruction was obtained. Dashed line 
represents the area covered by CRL2159 cells, occupying ~40 % of well 
area. (d) CRL1790 normal colon epithelium cells after RF exposure. The color 
bar represents the normalized values as percentage change from dark blue 
(0%) to red (100%). 
 





















































































When the nanoparticles are excited by the RF-field, they 
produce a faster rate of temperature change of cells and tissue 
at certain frequencies than untreated cells and tissue, i.e. those 
that do not contain nanoparticles. In the example presented in 
this paper, the frequency 2.5999 GHz was chosen. Even if the 
excitation causes direct heating of the cells and tissue, the faster 
rate of heating by the nanoparticles generates a temperature 
difference that can still be imaged by EIT. Thus, the location of 
the nanoparticles is indicated by a ‘hot-spot’ in the EIT image. 
A. Choice of Frequency 
It was observed that at frequencies 2.265 GHz, 2.599 GHz, 
and 2.5999 GHz, the GNP-based solution provided a heating 
rate higher than the solution based on PBS. However, despite 
the larger observed temperature increases of the GNP-CS 
solution higher at frequencies 2.265 GHz and 2.599 GHz, the 
smallest rate increase in the PBS solution was achieved at 
2.5999 GHz, which corresponds to the case of the lowest 
elevation of temperature in a human tissue and consequently, 
the lowest risk to damage it. Furthermore, the lowest rate in the 
tissue provides a possibility to avoid impedance changes in the 
corresponding regions, which will improve accuracy results 
provided by the EIT system. Thus, 2.5999 GHz was 
consequently chosen as the optimal frequency for GNP heating 
in the further experiments. 
The efficiency of the method for determination of an optimal 
frequency for GNP heating results in Fig. 6. Figs. 6(a)-(b) 
shown the reconstructed EIT images of two different solutions, 
which were placed on the PCB-unit, as shown in Fig. 6(c), and 
excited at 2.5999 GHz. Comparing the obtained results, it 
should be noted when GNPs are added to the solution, the 
response to the electromagnetic field excitation at 2.5999 GHz 
is higher in nanoparticles than in the surrounding PBS medium, 
which validates a correct frequency choice. 
However, identification of the optimal frequency for GNP 
heating based on temperature measurements is time consuming 
and does not provide information over a large frequency 
interval. As an alternative approach, for future work, an optimal 
frequency for GNP heating can be identified based on the 
highest absorption coefficient over a given frequency interval 
for a solution placed in a waveguide. The absorption coefficient 
can be determined by the law of conservation of energy, where 
the energy balance is given by 𝐴 = 1 − 𝑅 − 𝑇; 𝐴 denotes the 
absorption coefficient, 𝑅 and 𝑇 are the reflection and the 
transmission coefficients, respectively, which can be measured. 
B. EIT of GNPs in Solution 
When stabilized GNPs are added to a solution, they will 
disperse rather than aggregate, and that makes accessing their 
response independently of the solution more difficult. As it was 
necessary to analyze how the GNPs respond to radio frequency 
exposure, their storage solution, PBS, was also tested 
independently. An aliquot of GNPs was separated from the PBS 
by centrifugation and added to fresh PBS just before 
experimentation, in order to limit dispersion. PBS was added to 
two 32-electrode PCB boards, adding a pellet of GNPs to only 
one of them. Both boards were placed in the waveguide, 
recording a reference before exposing both solutions to RF for 
5 minutes. Fig. 6 shows the images produced from the EIT 
recording, after exposure, where the difference between the 
PBS solution (Fig. 6(a)) and the PBS plus GNP-CS (Fig. 6(b)) 
is apparent. The PBS solution showed a change from the 
reference of around 25%, representing a small change in image 
contrast on the reconstructed image, and a standard deviation 
below 0.4% for twenty repeats. Adding the GNP-CS aliquot to 
the PBS solution caused a recorded difference on average of 
80% and enhanced contrast on the resulting image. From the 
two obtained images it is apparent that the GNPs are more 
greatly affected by the RF exposure than their surrounding 
medium, being consistent with the real position of the GNPs 
inside the PCB well. Fig. 6(c) shows the GNP aliquot after 5 
minutes of being added in the PBS solution, and while the 
dispersion of the GNPs cannot be controlled, it correlates with 
the EIT image produced. Although from the produced EIT 
images the borders of the GNP aliquot cannot be defined, the 
presence of the nanoparticles can easily be identified. The 
uncontrolled dispersion of the GNPs could also explain the 
standard deviation of 4.37% for twenty repeats of the 
experiments, as shown in Table I. 
C. Confocal Confirmation of GNPs Targeting Colorectal 
Cancer Cells 
Targeting cancer cells through overexpressed receptors located 
on the cell’s surface is a widely utilized method of cancer cell 
identification. Folate receptors are found overexpressed in a 
large variety of cancer cell types whereas healthy cells are much 
less likely to express these receptors. Colorectal cancer cells 
overexpress folic acid receptors while colon epithelium cells 
have a weak expression of these receptors, and thus targeting 
folate receptors can be used to differentiate between cancerous 
and healthy colorectal tissue. Immunocytochemistry was used 
to image folate receptors on both cell lines, in order to confirm 
overexpression (Fig. 7). Confocal imaging of colon epithelium 
cells (Fig. 7(a)) showed absence of anti-FR-α antibodies 
indicating this receptor was absent or minimally expressed in 
normal colonic cells. In contrast, colorectal cancer cells (Fig. 
7(b)) presented a strong fluorescent signal indicative of FR-α 
overexpression. For both cell lines, horse serum was used to 
inhibit any unwanted signals and non-specific binding of 
primary antibodies to the antigen receptors. The resulting 
images confirmed that folate receptors could be used to 
differentiate normal and cancer cell lines. 
GNPs were functionalized with folic acid, and to allow simple 
confocal microscopy visualization, the GNP-FA constructs 
were labelled with FITC [38]. In order to assess the targeting 
ability, CRL1790 and CRL2159 cells were incubated with the 
FITC labelled GNP-FA construct and prepared for confocal 
microscopy. Fig. 7 shows the resulting images for both cell 
lines where the cells nuclei were counterstained using DAPI 
mounting media and stained blue. In colon epithelium cells 
(Fig. 7(c)), well-defined nuclei can be identified, and no green 
fluorescence is present, suggesting a lack of GNPs. However, 
in colorectal cancer cells (Fig. 7(d)), particles emitting strong 
green fluorescence are present in the cell’s cytoplasm, 




are associated with the internalization of the GNPs inside the 
cytoplasm via receptor-mediated endocytosis (RME) [35].  
 
D. EIT of GNPs Incubated with Cells 
To confirm the ability of EIT to detect GNPs against a 
complex surrounding, colorectal cancer cells were incubated 
with cell culture media, with GNP-CS, or with functionalized 
GNPs (GNP-FA). Fig. 8 shows the EIT images obtained after 5 
minutes RF exposure. When incubated without any GNPs, the 
CRL2159 cells did not produce a discernible change on the EIT 
image, and the change to reference was calculated to around 
8%. This was expected as the cells themselves do not suffer 
great changes during the short time period, and no changes in 
the surrounding medium are expected either, which confirms 
the weak interaction with the RF-field. Twenty experiments 
were repeated with a standard deviation <1%. Colorectal cancer 
cells incubated with citrate-coated GNPs produced a larger 
change in the EIT recording (around 18%) however the change 
was not enough to create contrast against the medium, contrary 
to what was seen previously with these GNPs in PBS. Since the 
cells were washed after incubation and before RF exposure in 
order to remove any unbound GNPs, and the GNP-CS were not 
functionalized, it was expected that the number of GNPs 
remaining in the cells would be greatly diminished, and thus 
this small change was expected. The cells incubated with GNP-
FA showed a greater change compared to the previous images, 
with approximately 40±2% (20 repeats of the experiment) 
change from reference. This change was reflected in the EIT 
image as the cell area was more clearly identifiable from the 
rest of the PCB area. The GNP-FA have been previously shown 
to be internalized by the colorectal cancer cells and thus were 
expected to remain in greater numbers after the wash steps. The 
change in impedance caused when GNPs were exposed to the 
RF field could be used to locate the CRL2159 cells’ position 
inside the PCB board, as it was comparable to the original 
placement of the cover slips. Repeating the experiment with 
both GNP solutions provided a standard deviation less than 3% 
(see Table II), which could be due to environmental 
temperature changes or to the washing process. No difference 
was observed between no exposure to RF and after exposure to 
RF, which confirms that GNP-FAs were not taken up in normal 
cells (Fig. 8(d)). GNP-FA should not be absorbed by the normal 
cells as they are designed to only target cancer cells. 
Since the PCB material does not allow for cells to be grown 
directly on its surface, this study was limited by the amount 
electrode area which could be covered with cells for GNP 
incubation. The cells were placed at the edge of the PCB well, 
the area covered by the cells towards the lower left corner of the 
image. The aim of this study was to show that changes 
occurring from exposing GNPs to an RF field at a frequency 
could be used to locate and create an image in cancer cells. 
V. CONCLUSION 
In this paper, a new method for location of functionalized 
gold nanoparticles using EIT has been presented. It 
demonstrated that functionalize GNPs in colorectal cell line can 
be located and validated with sufficient contrast change in the 
EIT images with RF stimulation. Images of impedance changes 
around 80±4% was found for a sample of citrate stabilized 
GNPs in PBS solution. It was also demonstrated that colorectal 
cancer cells incubated with culture media, with internalisation 
of GNPs into the colorectal cancer cells, resulted in an 
impedance change of approximately 40±2%. This change was 
reflected in the EIT image as the cell area was more clearly 
identifiable from the rest of the area. The demonstrates EIT can 
locate clusters functionalised GNPs (with core sizes below 2 
nm) in human cells by imaging the change in impedance before 
and after the GNPs have been stimulated by RF. 
The limit of GNPs detected through EIT is conditional on RF 
power. Furthermore, it is predicted that the amount of GNPs 
required to image in in vivo conditions varies from 2D cell 
culture conditions. Therefore, future work will seek to calculate 
the limit of detection of the technique in an animal model.  
Future work will also focus on developing a system for an 
animal model to validate the new imaging approach and it is 
hoped that this will lead to a system that can be used on humans 
for locating nanoparticle-based drugs. The results in this paper 
demonstrate the potential of this new methods to provide 
images of GNPs in the tumor cells. Furthermore, the proposed 
system can potentially be used with iron-oxide nanoparticles 
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